Benitec Biopharma Inc. (BNTC) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $3.00K; Additional Paid in Capital, Common StockUSD $451.69M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-963.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $3.00K; Additional Paid in Capital, Common StockUSD $445.19M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-952.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $3.00K; Additional Paid in Capital, Common StockUSD $437.22M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-883.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $331.49M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-750.00K.
Benitec Biopharma Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.00K | $451.69M | $-963.00K | $-273.72M | $177.01M | 12 month · $6.27M | 12 month · $26.41M |
| 2026-03-31 | $0.00 | $3.00K | $445.19M | $-952.00K | $-260.91M | $183.33M | (m) | 3 month · $7.59M |
| 2025-12-31 | $0.00 | $3.00K | $437.22M | $-883.00K | $-248.98M | $187.36M | 3 month · $6.26M | 3 month · $7.38M |
| 2025-09-30 | $0.00 | $2.00K | $331.49M | $-750.00K | $-237.14M | $93.60M | (m) | 3 month · $5.18M |
| 2025-06-30 | $0.00 | $2.00K | $326.31M | $-839.00K | $-228.18M | $97.30M | 12 month · $2.25M | 12 month · $17.43M |
| 2025-03-31 | $0.00 | $2.00K | $310.31M | $-716.00K | $-212.03M | $97.57M | 3 month · $2.25M | 3 month · $7.74M |
| 2024-12-31 | $0.00 | $2.00K | $279.30M | $-688.00K | $-202.68M | $75.94M | (m) | 3 month · $3.14M |
| 2024-09-30 | (m) | $1.00K | $260.49M | $-993.00K | $-195.32M | $64.18M | (m) | 3 month · $435.00K |
| 2024-06-30 | $0.00 | $1.00K | $238.40M | $-892.00K | $-190.26M | $47.25M | (m) | 12 month · $830.00K |
| 2024-03-31 | (m) | $0.00 | $197.87M | $-835.00K | $-185.54M | $11.50M | (m) | 3 month · $192.00K |
| 2023-12-31 | (m) | $0.00 | $197.68M | $-952.00K | $-181.26M | $15.47M | (m) | 3 month · $93.00K |
| 2023-09-30 | (m) | $0.00 | $197.55M | $-780.00K | $-174.46M | $22.31M | (m) | 3 month · $91.00K |
| 2023-06-30 | (m) | $0.00 | $168.92M | $-830.00K | $-167.89M | $202.00K | (m) | 12 month · $452.00K |
| 2023-03-31 | (m) | $3.00K | $168.79M | $-853.00K | $-163.23M | $4.71M | (m) | 3 month · $71.00K |
| 2022-12-31 | (m) | $3.00K | $168.72M | $-898.00K | $-158.83M | $8.99M | (m) | 3 month · $-48.00K |
| 2022-09-30 | (m) | $3.00K | $168.77M | $-738.00K | $-153.42M | $14.61M | (m) | 3 month · $302.00K |
| 2022-06-30 | (m) | $0.00 | $152.45M | $-1.25M | $-148.33M | $2.88M | (m) | 12 month · $870.00K |
| 2022-03-31 | (m) | $1.00K | $152.28M | $-1.51M | $-143.26M | $7.52M | (m) | 3 month · $192.00K |
| 2021-12-31 | (m) | $1.00K | $152.09M | $-1.27M | $-139.99M | $10.84M | (m) | 3 month · $239.00K |
| 2021-09-30 | (m) | $1.00K | $151.85M | $-1.22M | $-135.16M | $15.47M | (m) | 3 month · $271.00K |
| 2021-06-30 | (m) | $1.00K | $151.58M | $-1.46M | $-130.12M | $20.01M | (m) | 12 month · $634.00K |
| 2021-03-31 | (m) | $5.00K | $138.63M | $-1.59M | $-126.12M | $10.93M | (m) | 3 month · $235.00K |
| 2020-12-31 | (m) | $4.00K | $138.40M | $-1.57M | $-122.21M | $14.62M | (m) | 3 month · $82.00K |
| 2020-09-30 | (m) | $1.00K | $128.85M | $-1.77M | $-119.34M | $7.74M | (m) | 3 month · $38.00K |
| 2020-06-30 | (m) | $0.00 | $128.83M | $-1.95M | $-116.64M | $10.24M | (m) | 12 month · $237.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $12.34M | (m) | 3 month · $88.00K |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $15.25M | (m) | 3 month · $37.00K |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $16.97M | (m) | 3 month · $55.00K |
| 2019-06-30 | (m) | $1.00K | $127.33M | $-1.86M | $-108.87M | $16.59M | (m) | 12 month · $672.00K |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $13.84M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |